Epitalon (AEDG): telomeres in cell culture

Epitalon is most often described as a peptide that lengthens telomeres. That claim rests on a small number of cell-culture studies. This article looks at those studies in detail: which cells were used, what was measured, what a 2025 independent study added, and what changes in telomere length in cultured cells can and cannot tell us. Our broader review of the Epitalon research programme covers its origins, the animal lifespan studies and the pineal research.

Terminology

Epitalon is the tetrapeptide alanine–glutamic acid–aspartic acid–glycine, abbreviated in single-letter code as AEDG. The same molecule appears in the literature as Epitalon, Epithalon and Epitalone^[1]. It is a synthetic peptide based on epithalamin, a natural extract of the pineal gland^[2]. The names refer to one compound. Different spellings can nevertheless scatter the literature across searches.

Why telomeres, and why cells

Telomeres are repetitive DNA sequences that cap the ends of chromosomes and shorten as cells divide. Telomerase is the enzyme that can extend them. Its catalytic subunit, hTERT, is absent or low in most normal human somatic cells. A landmark 1998 experiment showed why this matters in culture. When telomerase-negative human cells were given the gene for hTERT, their telomeres lengthened and they divided well beyond their normal lifespan while keeping a normal karyotype^[3]. That study established a causal link between telomere shortening and the replicative senescence of cells in culture. It also showed that telomere length can be changed deliberately in a dish.

The cell studies

The early fibroblast studies

The first report described telomerase-negative human fetal fibroblasts. When Epitalon was added to the culture, the cells expressed telomerase's catalytic subunit, showed telomerase activity and had longer telomeres^[4]. A follow-up used primary lung fibroblasts from a fetus, which normally stopped dividing at the 34th passage. With Epitalon, telomeres returned to a length comparable with early passages, and the cells made ten extra divisions, reaching 44 passages and continuing to divide^[5]. The authors interpreted this as overcoming the Hayflick limit, the finite number of divisions normal cells can undergo.

Both studies came from the research network that developed Epitalon and were published as short reports. The published abstracts give limited methodological detail.

Lymphocytes: effects in both directions

A 2019 study incubated stimulated blood lymphocytes from five younger and six middle-aged men with AEDG. Relative telomere length changed significantly in 7 of the 11 men. It increased in five, by 18% to 156%, and decreased in two. The authors described a tendency towards normalisation: telomeres lengthened where they were initially shorter than the group average and shortened where they were initially longer^[6]. This is a small study with results in both directions. It does not describe a simple lengthening effect.

The 2025 independent study

The most informative recent work came from a group at Brunel University London, independent of the developers. They treated normal human epithelial cells and fibroblasts, together with two breast cancer cell lines, 21NT and BT474. In the normal cells, telomeres lengthened with increasing Epitalon concentration, accompanied by higher hTERT expression and telomerase activity. In the cancer cells, telomeres also lengthened significantly, but mainly through alternative lengthening of telomeres (ALT) rather than telomerase. ALT activity rose only slightly in the normal cells^[7].

A published correction replaced the original versions of three of the paper's figures, those showing telomere length, hTERT and telomerase measurements, and ALT activity^[8]. Readers relying on the figures should use the corrected versions.

The cancer-cell finding

ALT is a telomerase-independent mechanism based on homologous recombination. It maintains telomeres in 10% to 15% of human cancers, including some with particularly poor outcomes, and is considered a target for cancer therapy^[9]. The observation that Epitalon was associated with increased telomere length through ALT in breast cancer cell lines therefore deserves attention^[7]. It comes from one study in two cell lines. It neither establishes that Epitalon promotes cancer nor rules it out. What it does show is that telomere lengthening is not specific to healthy cells, and that the same effect can have different meanings in different cell types.

How telomeres are measured

Telomere length is measured in several ways, and they do not always agree. A blinded comparison of Southern blotting and quantitative PCR on the same samples, carried out in two independent laboratories, found both methods reproducible. However, qPCR was less precise, and the relationship between the two methods was not linear^[10]. The Epitalon studies used different techniques, including in situ hybridisation on chromosomes^[6] and qPCR with immunofluorescence^[7]. Percentage changes from different methods are not directly comparable.

Related cell research not measuring telomere length

Other recent cell studies have looked at telomerase or at markers of cellular ageing without measuring telomere length directly:

• Bovine oocytes. Epitalon, used to activate telomerase, improved oocyte maturation and the hatching of thawed embryos in culture^[11].
• Mouse oocytes. Epitalon reduced reactive oxygen species and markers of damage in oocytes ageing in vitro after ovulation^[2].
• Stem cells. In human periodontal ligament and gingival stem cells, AEDG reduced expression of the senescence markers p16 and p21 during long-term culture^[12]. In neurons derived from fetal stem cells, AEDG reduced p21 expression and β-galactosidase activity, another marker of cellular senescence^[13].

These findings describe cell quality or senescence markers under particular culture conditions. They are not measures of telomere length.

What in-vitro telomere changes establish

In-vitro telomere changes can show that a compound affects telomerase or telomere maintenance in a given cell type, under given conditions, at given concentrations. They cannot show:

• Effects in a whole organism. Concentrations, exposure times and delivery in culture differ from those in a living body.
• Effects on ageing. Longer telomeres in cultured cells are a cellular measurement, not a measure of how an organism ages.
• Benefit. Longer telomeres are not automatically desirable. In a Mendelian randomisation study of more than 400,000 disease cases, genetically longer telomeres were generally associated with a higher risk of several cancers^[14].
• Safety. The cancer cell findings described above raise questions that culture studies alone cannot answer.

Summary

The evidence linking Epitalon (AEDG) to telomeres comes from a small number of cell-culture studies. The early fibroblast reports, from the developers' network, described telomerase activation, telomere elongation and extended cell division. A lymphocyte study found changes in both directions. A 2025 independent study, whose figures were later corrected, found telomere lengthening in normal cells through telomerase and in breast cancer cells through ALT. These are genuine laboratory observations. They do not establish effects on ageing, lifespan or health in people.